BioCryst Pharmaceuticals Inc
BCRX8.375USD
+0.425+5.35%
交易中 （美东）报价延迟15分钟
1.75B总市值
亏损市盈率 TTM
关于 BioCryst Pharmaceuticals Inc 公司
BioCryst Pharmaceuticals, Inc. 是一家专注于改善补体介导疾病和其他罕见疾病患者生活的生物技术公司。该公司利用其在设计方面的专业知识开发一流的口服小分子和蛋白质疗法，以治疗难治疾病。其上市产品包括用于预防遗传性血管性水肿 (HAE) 发作的口服每日一次 ORLADEYO 和用于治疗美国急性无并发症流感的 RAPIVAB（帕拉米韦注射液）。其其他产品和候选产品包括 BCX10013、RAPIACTA（帕拉米韦注射液）、PERAMIFLU（帕拉米韦注射液）和早期发现项目。BCX10013 是一种强效且特异的 D 因子抑制剂。RAPIACTA 专注于无并发症的季节性流感。RAPIVAB（帕拉米韦注射液）在美国获批用于治疗 6 个月及以上患者的急性无并发症流感。
公司简介
公司代码BCRX
公司名称BioCryst Pharmaceuticals Inc
上市日期Mar 04, 1994
CEOMr. Charles K. Gayer
员工数量580
证券类型Ordinary Share
年结日Mar 04
公司地址4505 Emperor Blvd Ste 200
城市DURHAM
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编27703-8457
电话19198591302
网址https://www.biocryst.com/
公司代码BCRX
上市日期Mar 04, 1994
CEOMr. Charles K. Gayer
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
89.76K
+16.18%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
40.33K
+44.91%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月12日 周六
更新时间: 7月12日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
股东类型
持股股东
占比
Investment Advisor
32.45%
Investment Advisor/Hedge Fund
29.96%
Hedge Fund
18.97%
Research Firm
3.20%
Private Equity
1.84%
Individual Investor
1.27%
Pension Fund
0.53%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Other
11.14%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
549
185.97M
88.87%
-12.50M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
2023Q1
554
177.87M
94.17%
-5.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
21.61M
10.33%
-230.66K
-1.06%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.89M
8.55%
+189.84K
+1.07%
Mar 31, 2025
Kynam Capital Management LP
8.93M
4.27%
-156.84K
-1.73%
Mar 31, 2025
Avoro Capital Advisors LLC
8.70M
4.16%
-3.17M
-26.68%
Mar 31, 2025
State Street Global Advisors (US)
7.81M
3.73%
+314.44K
+4.19%
Mar 31, 2025
Alkeon Capital Management LLC
6.00M
2.87%
+109.73K
+1.86%
Mar 31, 2025
Two Sigma Investments, LP
5.27M
2.52%
+992.22K
+23.22%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
2.48%
-2.95M
-36.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.96M
2.37%
+136.90K
+2.84%
Mar 31, 2025
RP Management, LLC
3.85M
1.84%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
3.3%
Invesco Biotechnology & Genome ETF
2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
1.83%
Virtus LifeSci Biotech Products ETF
1.66%
ALPS Medical Breakthroughs ETF
1.27%
SPDR S&P Biotech ETF
0.68%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Main Thematic Innovation ETF
0.58%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Invesco NASDAQ Future Gen 200 ETF
0.38%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比3.3%
Invesco Biotechnology & Genome ETF
占比2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.83%
Virtus LifeSci Biotech Products ETF
占比1.66%
ALPS Medical Breakthroughs ETF
占比1.27%
SPDR S&P Biotech ETF
占比0.68%
First Trust Small Cap Growth AlphaDEX Fund
占比0.66%
Main Thematic Innovation ETF
占比0.58%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.39%
Invesco NASDAQ Future Gen 200 ETF
占比0.38%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
